In the absence of a major new molecule coming forward or franchise expansion, Roche's analyst event at the American Society for Clinical Oncology annual meeting fell back on perennial themes, emphasizing the depth and breadth of its oncology business during its portfolio review – with no shortage of superlatives.
The back-to-basics focus on franchise management may reflect Roche’s current time of transition. Chief executive officer Bill Anderson took the...








